CHMP backs approval of basket of drugs

On Friday, EMA's CHMP recommended approval of a host of therapies, including Rydapt midostaurin to treat acute myelogenous leukemia (AML), and Verkazia ciclosporin to treat severe vernal keratoconjunctivitis, a rare eye allergy.

CHMP backed approval of Rydapt from

Read the full 376 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE